Your session is about to expire
← Back to Search
Sucrase for Short Bowel Syndrome
Study Summary
This trial is testing whether exogenous sucrase can improve sucrose digestion in short gut syndrome with intestinal failure patients.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You need to follow a diet that includes sugar.I am currently receiving IV antibiotics for a confirmed blood infection.You cannot receive nutrition through a feeding tube.I have short bowel syndrome and need help for more than half of my nutrition or hydration.I am of any age.
- Group 1: Sucrase intervention followed by placebo
- Group 2: Placebo followed by sucrase intervention
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What potential hazards are associated with the ingestion of Sucrase?
"Our team at Power assigned Sucrase a score of 2, signifying that clinical data exists to support the drug's safety but there is no evidence yet attesting to its efficacy."
How many subjects have been enrolled in this experiment?
"Affirmative. According to clinicaltrials.gov, this study is currently accepting applicants since its first posting on February 2nd 2022 and last edit on October 27th 2022. There are 10 positions open across two medical facilities."
Is recruitment of participants still open for this investigation?
"According to the clinicaltrials.gov website, this research is currently in the process of recruiting participants. The experiment was listed on February 2nd 2022 and recent modifications occurred on October 27th 2022."
Share this study with friends
Copy Link
Messenger